|
G |
ACHE |
acetylcholinesterase (Yt blood group) |
multiple interactions |
ISO |
[lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in increased activity of ACHE protein; [zinc chloride co-treated with Sodium Selenite] inhibits the reaction [[lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in increased activity of ACHE protein] |
CTD |
PMID:36646412 |
|
NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
|
|
G |
ACSL4 |
acyl-CoA synthetase long chain family member 4 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of ACSL4 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr X:109,641,335...109,733,257
Ensembl chr X:109,624,244...109,733,403
|
|
G |
ACTB |
actin beta |
decreases expression |
EXP |
lead chloride results in decreased expression of ACTB protein |
CTD |
PMID:24419708 |
|
NCBI chr 7:5,527,148...5,530,601
Ensembl chr 7:5,526,409...5,563,902
|
|
G |
ADK |
adenosine kinase |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of ADK mRNA |
CTD |
PMID:18654764 |
|
NCBI chr10:74,151,221...74,709,290
Ensembl chr10:74,151,202...74,709,963
|
|
G |
AKR1B10 |
aldo-keto reductase family 1 member B10 |
multiple interactions increases expression |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of AKR1B10 mRNA lead chloride results in increased expression of AKR1B10 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 7:134,527,567...134,541,412
Ensembl chr 7:134,527,567...134,541,412
|
|
G |
AKR1C1 |
aldo-keto reductase family 1 member C1 |
multiple interactions increases expression |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of AKR1C1 mRNA lead chloride results in increased expression of AKR1C1 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr10:4,963,415...4,983,283
Ensembl chr10:4,963,253...4,983,283
|
|
G |
AKR1C2 |
aldo-keto reductase family 1 member C2 |
multiple interactions increases expression |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of AKR1C2 mRNA lead chloride results in increased expression of AKR1C2 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr10:4,987,775...5,018,000
Ensembl chr10:4,987,775...5,018,031
|
|
G |
ANXA1 |
annexin A1 |
increases expression |
EXP |
lead chloride results in increased expression of ANXA1 protein |
CTD |
PMID:24419708 |
|
NCBI chr 9:73,151,865...73,170,393
Ensembl chr 9:73,151,865...73,170,393
|
|
G |
ATF4 |
activating transcription factor 4 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] affects the expression of ATF4 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,683
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression |
EXP |
lead chloride results in decreased expression of BCL2 protein |
CTD |
PMID:24419708 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BHLHE40 |
basic helix-loop-helix family member e40 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of BHLHE40 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 3:4,979,437...4,985,323
Ensembl chr 3:4,979,437...4,985,323
|
|
G |
CALD1 |
caldesmon 1 |
decreases expression |
EXP |
lead chloride results in decreased expression of CALD1 protein |
CTD |
PMID:24419708 |
|
NCBI chr 7:134,745,467...134,970,729
Ensembl chr 7:134,744,252...134,970,729
|
|
G |
CASP3 |
caspase 3 |
increases cleavage multiple interactions |
EXP ISO |
lead chloride results in increased cleavage of CASP3 protein [lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in increased expression of CASP3 protein; [zinc chloride co-treated with lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in increased expression of CASP3 protein [[lead chloride results in increased abundance of Lead] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of CASP3 protein; [[lead chloride results in increased abundance of Lead] which co-treated with methylmercuric chloride] results in increased expression of CASP3 protein |
CTD |
PMID:24419708 PMID:32179164 PMID:36646412 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP9 |
caspase 9 |
increases cleavage |
EXP |
lead chloride results in increased cleavage of CASP9 protein |
CTD |
PMID:24419708 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
[[lead chloride results in increased abundance of Lead] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of CAT protein; [[lead chloride results in increased abundance of Lead] which co-treated with methylmercuric chloride] results in increased expression of CAT protein [lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in decreased activity of CAT protein; [zinc chloride co-treated with Sodium Selenite] inhibits the reaction [[lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in decreased activity of CAT protein]; Sodium Selenite inhibits the reaction [[lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in decreased activity of CAT protein] |
CTD |
PMID:32179164 PMID:36646412 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCL3 |
C-C motif chemokine ligand 3 |
multiple interactions |
EXP |
lead chloride promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein] |
CTD |
PMID:36416909 |
|
NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169
|
|
G |
CCL5 |
C-C motif chemokine ligand 5 |
increases secretion |
EXP |
lead chloride results in increased secretion of CCL5 protein |
CTD |
PMID:16099135 |
|
NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
|
|
G |
CCNA1 |
cyclin A1 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in decreased expression of CCNA1 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr13:36,431,517...36,442,870
Ensembl chr13:36,431,520...36,442,870
|
|
G |
CCT2 |
chaperonin containing TCP1 subunit 2 |
decreases expression |
EXP |
lead chloride results in decreased expression of CCT2 protein |
CTD |
PMID:24419708 |
|
NCBI chr12:69,585,459...69,601,570
Ensembl chr12:69,585,426...69,601,570
|
|
G |
CCT5 |
chaperonin containing TCP1 subunit 5 |
decreases expression |
EXP |
lead chloride results in decreased expression of CCT5 protein |
CTD |
PMID:24419708 |
|
NCBI chr 5:10,249,921...10,266,412
Ensembl chr 5:10,249,929...10,266,389
|
|
G |
CREB1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] affects the expression of CREB1 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
increases secretion multiple interactions |
EXP |
lead chloride results in increased secretion of CXCL8 protein lead chloride promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CXCL8 protein] |
CTD |
PMID:16099135 PMID:36416909 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
increases expression |
ISO |
lead chloride results in increased expression of CYP1A1 mRNA |
CTD |
PMID:23503628 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP2A6 |
cytochrome P450 family 2 subfamily A member 6 |
multiple interactions increases expression |
ISO |
[lead chloride affects the localization of NFE2L2 protein] promotes the reaction [NFE2L2 protein binds to CYP2A5 promoter]; NFE2L2 protein affects the reaction [lead chloride results in increased expression of CYP2A5 mRNA] |
CTD |
PMID:20402460 |
|
NCBI chr19:40,843,541...40,850,447
Ensembl chr19:40,843,541...40,850,447
|
|
G |
DDAH2 |
DDAH family member 2, ADMA-independent |
increases expression |
EXP |
lead chloride results in increased expression of DDAH2 protein |
CTD |
PMID:24419708 |
|
NCBI chr 6:31,727,040...31,730,263
Ensembl chr 6:31,727,038...31,730,617
|
|
G |
EEA1 |
early endosome antigen 1 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of EEA1 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr12:92,770,637...92,929,295
Ensembl chr12:92,770,637...92,929,331
|
|
G |
EEF1B2 |
eukaryotic translation elongation factor 1 beta 2 |
increases expression |
EXP |
lead chloride results in increased expression of EEF1B2 protein |
CTD |
PMID:24419708 |
|
NCBI chr 2:206,159,609...206,162,928
Ensembl chr 2:206,159,585...206,162,928
|
|
G |
EEF1D |
eukaryotic translation elongation factor 1 delta |
decreases expression |
EXP |
lead chloride results in decreased expression of EEF1D protein |
CTD |
PMID:24419708 |
|
NCBI chr 8:143,579,728...143,597,415
Ensembl chr 8:143,579,697...143,599,541
|
|
G |
EIF2S1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation |
EXP |
lead chloride results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:25410796 |
|
NCBI chr14:67,360,328...67,386,516
Ensembl chr14:67,360,328...67,386,516
|
|
G |
ELK1 |
ETS transcription factor ELK1 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] affects the expression of ELK1 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr X:47,635,520...47,650,604
Ensembl chr X:47,635,521...47,650,604
|
|
G |
ENO1 |
enolase 1 |
increases expression |
EXP |
lead chloride results in increased expression of ENO1 protein |
CTD |
PMID:24419708 |
|
NCBI chr 1:8,861,000...8,878,686
Ensembl chr 1:8,861,000...8,879,190
|
|
G |
ERG28 |
ergosterol biosynthesis 28 homolog |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of ERG28 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr14:75,649,791...75,660,876
Ensembl chr14:75,649,791...75,660,876
|
|
G |
ESR1 |
estrogen receptor 1 |
affects response to substance increases activity decreases expression multiple interactions |
EXP |
ESR1 protein affects the susceptibility to lead chloride lead chloride results in increased activity of ESR1 protein lead chloride results in decreased expression of ESR1 mRNA; lead chloride results in decreased expression of ESR1 protein Estradiol promotes the reaction [lead chloride results in decreased expression of ESR1 mRNA]; Estradiol promotes the reaction [lead chloride results in decreased expression of ESR1 protein]; lead chloride inhibits the reaction [Estradiol binds to ESR1 protein]; lead chloride promotes the reaction [Estradiol results in decreased expression of ESR1 protein] |
CTD |
PMID:12746304 |
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
EXOC5 |
exocyst complex component 5 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of EXOC5 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr14:57,200,507...57,268,905
Ensembl chr14:57,200,507...57,268,905
|
|
G |
F2R |
coagulation factor II thrombin receptor |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of F2R mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 5:76,716,126...76,735,770
Ensembl chr 5:76,716,126...76,735,770
|
|
G |
GABRD |
gamma-aminobutyric acid type A receptor subunit delta |
increases expression |
ISO |
lead chloride results in increased expression of GABRD mRNA |
CTD |
PMID:19651682 |
|
NCBI chr 1:2,019,345...2,030,758
Ensembl chr 1:2,019,329...2,030,758
|
|
G |
GAS1 |
growth arrest specific 1 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in decreased expression of GAS1 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 9:86,944,362...86,947,506
Ensembl chr 9:86,944,362...86,947,506
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
multiple interactions decreases expression increases expression |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of GCLC mRNA lead chloride results in decreased expression of GCLC protein lead chloride results in increased expression of GCLC mRNA |
CTD |
PMID:18654764 PMID:30359721 |
|
NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970
|
|
G |
GFAP |
glial fibrillary acidic protein |
decreases expression |
ISO |
lead chloride results in decreased expression of GFAP mRNA |
CTD |
PMID:19651682 |
|
NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937
|
|
G |
GM2A |
ganglioside GM2 activator |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of GM2A mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 5:151,253,185...151,270,440
Ensembl chr 5:151,212,150...151,270,440
|
|
G |
GNA13 |
G protein subunit alpha 13 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of GNA13 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr17:65,009,289...65,056,740
Ensembl chr17:65,009,289...65,056,740
|
|
G |
GPNMB |
glycoprotein nmb |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of GPNMB mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 7:23,246,775...23,275,108
Ensembl chr 7:23,235,967...23,275,108
|
|
G |
GPX2 |
glutathione peroxidase 2 |
multiple interactions increases expression |
EXP ISO |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of GPX2 mRNA lead chloride results in increased expression of GPX2 mRNA |
CTD |
PMID:18654764 PMID:23503628 |
|
NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,746
|
|
G |
GRIN1 |
glutamate ionotropic receptor NMDA type subunit 1 |
increases expression |
ISO |
lead chloride results in increased expression of GRIN1 mRNA |
CTD |
PMID:19651682 |
|
NCBI chr 9:137,139,154...137,168,756
Ensembl chr 9:137,138,346...137,168,756
|
|
G |
GSTM1 |
glutathione S-transferase mu 1 |
decreases expression |
EXP |
lead chloride results in decreased expression of GSTM1 protein |
CTD |
PMID:30359721 |
|
NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039
|
|
G |
HEG1 |
heart development protein with EGF like domains 1 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of HEG1 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 3:124,965,710...125,055,997
Ensembl chr 3:124,965,710...125,055,997
|
|
G |
HIC1 |
HIC ZBTB transcriptional repressor 1 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] affects the expression of HIC1 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr17:2,055,103...2,063,241
Ensembl chr17:2,054,154...2,063,241
|
|
G |
HMBS |
hydroxymethylbilane synthase |
decreases activity |
EXP ISO |
lead chloride results in decreased activity of HMBS protein Lead Chloride decreases activity of purified Hmbs protein |
CTD RGD |
PMID:10416826 PMID:994723 |
RGD:25440497 |
NCBI chr11:119,084,881...119,093,549
Ensembl chr11:119,084,866...119,093,834
|
|
G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of HMGCR mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001
|
|
G |
HMGCS1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of HMGCS1 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 5:43,287,470...43,313,412
Ensembl chr 5:43,287,470...43,313,512
|
|
G |
HMOX1 |
heme oxygenase 1 |
decreases expression multiple interactions increases expression |
ISO |
lead chloride results in decreased expression of HMOX1 mRNA [lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in decreased expression of HMOX1 protein; [zinc chloride co-treated with Sodium Selenite] inhibits the reaction [[lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in decreased expression of HMOX1 protein]; Sodium Selenite inhibits the reaction [[lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in decreased expression of HMOX1 protein] lead chloride results in increased expression of HMOX1 mRNA |
CTD |
PMID:20402460 PMID:23503628 PMID:23916686 PMID:36646412 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HNRNPD |
heterogeneous nuclear ribonucleoprotein D |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in decreased expression of HNRNPD mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 4:82,352,498...82,373,991
Ensembl chr 4:82,352,498...82,374,503
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
affects localization increases expression decreases expression |
ISO EXP |
lead chloride affects the localization of HSPA5 protein lead chloride results in increased expression of HSPA5 protein lead chloride results in decreased expression of HSPA5 protein |
CTD |
PMID:19720107 PMID:21073006 PMID:24419708 |
|
NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382
|
|
G |
HSPA9 |
heat shock protein family A (Hsp70) member 9 |
decreases expression |
EXP |
lead chloride results in decreased expression of HSPA9 protein |
CTD |
PMID:24419708 |
|
NCBI chr 5:138,553,756...138,575,401
Ensembl chr 5:138,553,756...138,575,675
|
|
G |
HSPB1 |
heat shock protein family B (small) member 1 |
increases expression |
EXP |
lead chloride results in increased expression of HSPB1 protein |
CTD |
PMID:24419708 |
|
NCBI chr 7:76,302,673...76,304,292
Ensembl chr 7:76,302,673...76,304,295
|
|
G |
HSPD1 |
heat shock protein family D (Hsp60) member 1 |
decreases expression |
EXP |
lead chloride results in decreased expression of HSPD1 protein |
CTD |
PMID:24419708 |
|
NCBI chr 2:197,486,584...197,500,274
Ensembl chr 2:197,486,584...197,516,737
|
|
G |
IFNG |
interferon gamma |
decreases expression multiple interactions |
EXP ISO |
lead chloride results in decreased expression of IFNG protein lead chloride results in decreased expression of IFNG mRNA [lead chloride results in increased abundance of Lead] which results in increased expression of IFNG protein; decabromobiphenyl ether promotes the reaction [[lead chloride results in increased abundance of Lead] which results in increased expression of IFNG protein]; lead chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; lead chloride inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:8975779 PMID:15843504 PMID:23503628 PMID:30836164 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IL10 |
interleukin 10 |
multiple interactions |
ISO |
[lead chloride results in increased abundance of Lead] promotes the reaction [decabromobiphenyl ether results in increased expression of IL10 protein]; [lead chloride results in increased abundance of Lead] which results in increased expression of IL10 protein; decabromobiphenyl ether promotes the reaction [[lead chloride results in increased abundance of Lead] which results in increased expression of IL10 protein] |
CTD |
PMID:30836164 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL12B |
interleukin 12B |
multiple interactions |
EXP |
lead chloride inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL12B protein] |
CTD |
PMID:36416909 |
|
NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,863
|
|
G |
IL13RA2 |
interleukin 13 receptor subunit alpha 2 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in decreased expression of IL13RA2 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr X:115,003,982...115,017,616
Ensembl chr X:115,003,975...115,019,977
|
|
G |
IL17A |
interleukin 17A |
multiple interactions |
ISO |
[lead chloride results in increased abundance of Lead] promotes the reaction [decabromobiphenyl ether results in increased expression of IL17A protein]; [lead chloride results in increased abundance of Lead] which results in increased expression of IL17A protein; decabromobiphenyl ether promotes the reaction [[lead chloride results in increased abundance of Lead] which results in increased expression of IL17A protein] |
CTD |
PMID:30836164 |
|
NCBI chr 6:52,186,375...52,190,638
Ensembl chr 6:52,186,375...52,190,638
|
|
G |
IL1B |
interleukin 1 beta |
decreases expression |
EXP ISO |
lead chloride results in decreased expression of IL1B protein lead chloride results in decreased expression of IL1B mRNA |
CTD |
PMID:15843504 PMID:23503628 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL2 |
interleukin 2 |
decreases expression |
EXP |
lead chloride results in decreased expression of IL2 protein |
CTD |
PMID:15183152 |
|
NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725
|
|
G |
IL4 |
interleukin 4 |
multiple interactions |
ISO |
[lead chloride results in increased abundance of Lead] which results in increased expression of IL4 protein; decabromobiphenyl ether promotes the reaction [[lead chloride results in increased abundance of Lead] which results in increased expression of IL4 protein] |
CTD |
PMID:30836164 |
|
NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
[lead chloride results in increased abundance of Lead] which results in increased expression of IL6 protein; decabromobiphenyl ether promotes the reaction [[lead chloride results in increased abundance of Lead] which results in increased expression of IL6 protein] [lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in increased expression of IL6 protein; Sodium Selenite promotes the reaction [[lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in increased expression of IL6 protein]; zinc chloride inhibits the reaction [Sodium Selenite promotes the reaction [[lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in increased expression of IL6 protein]] |
CTD |
PMID:30836164 PMID:36646412 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
INSIG1 |
insulin induced gene 1 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of INSIG1 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 7:155,297,878...155,310,235
Ensembl chr 7:155,297,776...155,310,235
|
|
G |
KCNS3 |
potassium voltage-gated channel modifier subfamily S member 3 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of KCNS3 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 2:17,877,847...17,932,958
Ensembl chr 2:17,877,847...18,361,616
|
|
G |
KLHL24 |
kelch like family member 24 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of KLHL24 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 3:183,635,623...183,684,519
Ensembl chr 3:183,635,610...183,684,519
|
|
G |
KLHL7 |
kelch like family member 7 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of KLHL7 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 7:23,105,785...23,177,914
Ensembl chr 7:23,105,758...23,177,914
|
|
G |
LAMP3 |
lysosomal associated membrane protein 3 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in decreased expression of LAMP3 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 3:183,122,215...183,163,813
Ensembl chr 3:183,122,215...183,163,839
|
|
G |
LYZ |
lysozyme |
decreases expression |
EXP |
lead chloride results in decreased expression of LYZ protein |
CTD |
PMID:24419708 |
|
NCBI chr12:69,348,381...69,354,234
Ensembl chr12:69,348,381...69,354,234
|
|
G |
MALAT1 |
metastasis associated lung adenocarcinoma transcript 1 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of MALAT1 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr11:65,497,738...65,506,516
Ensembl chr11:65,497,640...65,508,073
|
|
G |
MAOA |
monoamine oxidase A |
multiple interactions |
ISO |
[[lead chloride results in increased abundance of Lead] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of MAOA protein |
CTD |
PMID:32179164 |
|
NCBI chr X:43,655,006...43,746,817
Ensembl chr X:43,654,907...43,746,817
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
increases expression |
EXP |
lead chloride results in increased expression of MAPK8 protein modified form |
CTD |
PMID:24419708 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
increases expression |
EXP |
lead chloride results in increased expression of MAPK9 protein modified form |
CTD |
PMID:24419708 |
|
NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
|
|
G |
MCU |
mitochondrial calcium uniporter |
decreases expression |
ISO |
lead chloride results in decreased expression of MCU protein |
CTD |
PMID:24881885 |
|
NCBI chr10:72,692,143...72,887,694
Ensembl chr10:72,692,143...72,887,694
|
|
G |
MT1A |
metallothionein 1A |
increases expression |
ISO |
lead chloride results in increased expression of MT1A mRNA |
CTD |
PMID:19720107 |
|
NCBI chr16:56,638,666...56,640,087
Ensembl chr16:56,638,666...56,640,087
|
|
G |
MT1X |
metallothionein 1X |
increases expression multiple interactions |
ISO |
lead chloride results in increased expression of MT1 mRNA [[lead chloride results in increased abundance of Lead] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of MT1 protein; [[lead chloride results in increased abundance of Lead] which co-treated with methylmercuric chloride] results in increased expression of MT1 protein |
CTD |
PMID:23503628 PMID:32179164 |
|
NCBI chr16:56,682,470...56,684,196
Ensembl chr16:56,682,470...56,684,196
|
|
G |
MT2A |
metallothionein 2A |
increases expression |
ISO |
lead chloride results in increased expression of MT2 mRNA |
CTD |
PMID:23503628 |
|
NCBI chr16:56,608,584...56,609,497
Ensembl chr16:56,608,584...56,609,497
|
|
G |
MYL6 |
myosin light chain 6 |
increases expression |
EXP |
lead chloride results in increased expression of MYL6 protein |
CTD |
PMID:24419708 |
|
NCBI chr12:56,158,359...56,161,579
Ensembl chr12:56,158,346...56,163,496
|
|
G |
NCAM1 |
neural cell adhesion molecule 1 |
decreases expression |
ISO |
lead chloride results in decreased expression of NCAM1 mRNA; lead chloride results in decreased expression of NCAM1 protein; lead chloride results in decreased expression of NCAM1 protein modified form |
CTD |
PMID:18499259 |
|
NCBI chr11:112,961,420...113,278,436
Ensembl chr11:112,961,275...113,278,436
|
|
G |
NEDD4 |
NEDD4 E3 ubiquitin protein ligase |
multiple interactions |
ISO |
[[lead chloride results in increased abundance of Lead] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased expression of NEDD4 protein; [[lead chloride results in increased abundance of Lead] which co-treated with methylmercuric chloride] results in decreased expression of NEDD4 protein |
CTD |
PMID:32179164 |
|
NCBI chr15:55,826,917...55,993,612
Ensembl chr15:55,826,922...55,993,660
|
|
G |
NEFH |
neurofilament heavy chain |
increases expression |
ISO |
lead chloride results in increased expression of NEFH mRNA |
CTD |
PMID:19651682 |
|
NCBI chr22:29,480,218...29,491,390
Ensembl chr22:29,480,218...29,491,390
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions decreases expression affects localization |
ISO EXP |
[lead chloride affects the localization of NFE2L2 protein] promotes the reaction [NFE2L2 protein binds to CYP2A5 promoter]; NFE2L2 protein affects the reaction [lead chloride results in increased expression of CYP2A5 mRNA] [lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in increased expression of NFE2L2 protein; [Sodium Selenite co-treated with zinc chloride] inhibits the reaction [[lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in increased expression of NFE2L2 protein] lead chloride results in decreased expression of NFE2L2 protein |
CTD |
PMID:20402460 PMID:30359721 PMID:36646412 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NOS1 |
nitric oxide synthase 1 |
increases expression decreases expression |
ISO EXP |
lead chloride results in increased expression of NOS1 protein lead chloride results in decreased expression of NOS1 mRNA; lead chloride results in decreased expression of NOS1 protein |
CTD |
PMID:24881885 PMID:25410796 |
|
NCBI chr12:117,208,142...117,361,626
Ensembl chr12:117,208,142...117,452,170
|
|
G |
NOS2 |
nitric oxide synthase 2 |
decreases expression increases expression multiple interactions |
ISO EXP |
lead chloride results in decreased expression of NOS2 mRNA lead chloride results in decreased expression of NOS2 mRNA; lead chloride results in decreased expression of NOS2 protein lead chloride results in increased expression of NOS2 mRNA lead chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]] |
CTD |
PMID:8975779 PMID:23503628 PMID:23916686 PMID:25410796 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NOS3 |
nitric oxide synthase 3 |
decreases expression |
EXP |
lead chloride results in decreased expression of NOS3 mRNA; lead chloride results in decreased expression of NOS3 protein |
CTD |
PMID:25410796 |
|
NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588
|
|
G |
NOX4 |
NADPH oxidase 4 |
increases expression |
EXP |
lead chloride results in increased expression of NOX4 protein |
CTD |
PMID:30359721 |
|
NCBI chr11:89,324,353...89,589,557
Ensembl chr11:89,324,353...89,498,187
|
|
G |
PDE7A |
phosphodiesterase 7A |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of PDE7A mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 8:65,714,334...65,842,064
Ensembl chr 8:65,714,334...65,842,322
|
|
G |
PDIA3 |
protein disulfide isomerase family A member 3 |
decreases expression |
EXP |
lead chloride results in decreased expression of PDIA3 protein |
CTD |
PMID:24419708 |
|
NCBI chr15:43,746,438...43,773,278
Ensembl chr15:43,746,394...43,773,279
|
|
G |
PGR |
progesterone receptor |
multiple interactions increases expression |
EXP |
Estradiol promotes the reaction [lead chloride results in increased expression of PGR mRNA]; Estradiol promotes the reaction [lead chloride results in increased expression of PGR protein]; fulvestrant inhibits the reaction [lead chloride results in increased expression of PGR mRNA]; fulvestrant inhibits the reaction [lead chloride results in increased expression of PGR protein]; lead chloride promotes the reaction [Estradiol results in increased expression of PGR mRNA]; lead chloride promotes the reaction [Estradiol results in increased expression of PGR protein] lead chloride results in increased expression of PGR mRNA; lead chloride results in increased expression of PGR protein |
CTD |
PMID:12746304 |
|
NCBI chr11:101,029,624...101,129,813
Ensembl chr11:101,029,624...101,129,813
|
|
G |
PLA2G4A |
phospholipase A2 group IVA |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of PLA2G4A mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 1:186,828,949...186,988,981
Ensembl chr 1:186,828,949...186,988,981
|
|
G |
PLIN3 |
perilipin 3 |
decreases expression |
EXP |
lead chloride results in decreased expression of PLIN3 protein |
CTD |
PMID:24419708 |
|
NCBI chr19:4,838,341...4,867,667
Ensembl chr19:4,838,341...4,867,694
|
|
G |
POU2F1 |
POU class 2 homeobox 1 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] affects the expression of POU2F1 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 1:167,220,885...167,427,345
Ensembl chr 1:167,220,876...167,427,345
|
|
G |
PTGR1 |
prostaglandin reductase 1 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of PTGR1 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 9:111,549,722...111,599,647
Ensembl chr 9:111,549,722...111,599,893
|
|
G |
RGCC |
regulator of cell cycle |
multiple interactions increases expression |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of RGCC mRNA lead chloride results in increased expression of RGCC mRNA |
CTD |
PMID:18654764 |
|
NCBI chr13:41,457,550...41,470,871
Ensembl chr13:41,457,550...41,470,871
|
|
G |
RNASE4 |
ribonuclease A family member 4 |
multiple interactions increases expression |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of RNASE4 mRNA lead chloride results in increased expression of RNASE4 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr14:20,684,560...20,701,216
Ensembl chr14:20,684,560...20,701,216
|
|
G |
RUSC1-AS1 |
RUSC1 antisense RNA 1 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of RUSC1-AS1 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 1:155,316,854...155,324,176
Ensembl chr 1:155,316,863...155,324,176
|
|
G |
S100A11 |
S100 calcium binding protein A11 |
increases expression |
EXP |
lead chloride results in increased expression of S100A11 protein |
CTD |
PMID:24419708 |
|
NCBI chr 1:152,032,506...152,037,004
Ensembl chr 1:152,032,506...152,047,907
|
|
G |
SCAMP1 |
secretory carrier membrane protein 1 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of SCAMP1 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 5:78,360,617...78,480,739
Ensembl chr 5:78,360,611...78,480,739
|
|
G |
SEPTIN5 |
septin 5 |
multiple interactions |
ISO |
[[lead chloride results in increased abundance of Lead] which co-treated with methylmercuric chloride] results in decreased expression of SEPTIN5 protein |
CTD |
PMID:32179164 |
|
NCBI chr22:19,714,503...19,723,319
Ensembl chr22:19,714,503...19,724,224
|
|
G |
SLC11A2 |
solute carrier family 11 member 2 |
increases expression |
ISO |
lead chloride results in increased expression of SLC11A2 mRNA |
CTD |
PMID:23503628 |
|
NCBI chr12:50,952,263...51,028,886
Ensembl chr12:50,979,401...51,028,566
|
|
G |
SLC22A8 |
solute carrier family 22 member 8 |
increases activity multiple interactions |
EXP |
lead chloride results in increased activity of SLC22A8 protein lead chloride promotes the reaction [SLC22A8 protein results in increased import of 6-carboxyfluorescein] |
CTD |
PMID:28629854 |
|
NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841
|
|
G |
SLC6A6 |
solute carrier family 6 member 6 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of SLC6A6 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 3:14,402,576...14,489,349
Ensembl chr 3:14,402,576...14,489,349
|
|
G |
SNHG12 |
small nucleolar RNA host gene 12 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in decreased expression of SNHG12 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 1:28,578,538...28,582,983
Ensembl chr 1:28,578,538...28,583,132
|
|
G |
SNRNP70 |
small nuclear ribonucleoprotein U1 subunit 70 |
multiple interactions |
ISO |
[[lead chloride results in increased abundance of Lead] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of SNRNP70 protein; [[lead chloride results in increased abundance of Lead] which co-treated with methylmercuric chloride] results in increased expression of SNRNP70 protein |
CTD |
PMID:32179164 |
|
NCBI chr19:49,085,451...49,108,604
Ensembl chr19:49,085,419...49,108,605
|
|
G |
SOD1 |
superoxide dismutase 1 |
decreases expression increases expression |
ISO |
lead chloride results in decreased expression of SOD1 mRNA lead chloride results in increased expression of SOD1 mRNA |
CTD |
PMID:23503628 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931
|
|
G |
SP1 |
Sp1 transcription factor |
multiple interactions |
ISO |
[[lead chloride results in increased abundance of Lead] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of SP1 protein; [[lead chloride results in increased abundance of Lead] which co-treated with methylmercuric chloride] results in increased expression of SP1 protein |
CTD |
PMID:32179164 |
|
NCBI chr12:53,380,176...53,416,446
Ensembl chr12:53,380,176...53,416,446
|
|
G |
SQLE |
squalene epoxidase |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of SQLE mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 8:124,998,505...125,022,283
Ensembl chr 8:124,998,497...125,022,283
|
|
G |
SRF |
serum response factor |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] affects the expression of SRF mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 6:43,171,269...43,181,506
Ensembl chr 6:43,171,269...43,181,506
|
|
G |
SRY |
sex determining region Y |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] affects the expression of SRY mRNA |
CTD |
PMID:18654764 |
|
NCBI chr Y:2,786,855...2,787,682
Ensembl chr Y:2,786,855...2,787,682
|
|
G |
ST8SIA2 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 |
decreases expression |
ISO |
lead chloride results in decreased expression of ST8SIA2 mRNA |
CTD |
PMID:18499259 |
|
NCBI chr15:92,393,881...92,468,728
Ensembl chr15:92,393,881...92,468,728
|
|
G |
ST8SIA4 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 |
decreases expression |
ISO |
lead chloride results in decreased expression of ST8SIA4 mRNA |
CTD |
PMID:18499259 |
|
NCBI chr 5:100,806,933...100,903,282
Ensembl chr 5:100,806,933...100,903,282
|
|
G |
STK26 |
serine/threonine kinase 26 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of STK26 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr X:132,023,302...132,075,943
Ensembl chr X:132,023,302...132,075,943
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
decreases expression |
ISO |
lead chloride results in decreased expression of TGFB1 mRNA |
CTD |
PMID:23503628 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TKT |
transketolase |
increases expression |
EXP |
lead chloride results in increased expression of TKT mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 3:53,224,712...53,256,022
Ensembl chr 3:53,224,712...53,256,052
|
|
G |
TMEM97 |
transmembrane protein 97 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of TMEM97 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr17:28,319,200...28,328,685
Ensembl chr17:28,319,200...28,328,685
|
|
G |
TNF |
tumor necrosis factor |
decreases expression multiple interactions |
EXP ISO |
lead chloride results in decreased expression of TNF protein [lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in increased expression of TNF protein; [Sodium Selenite co-treated with zinc chloride] affects the reaction [[lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in increased expression of TNF protein]; Sodium Selenite affects the reaction [[lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in increased expression of TNF protein]; zinc chloride inhibits the reaction [[lead chloride co-treated with Cadmium Chloride co-treated with Mercuric Chloride co-treated with sodium arsenite] results in increased expression of TNF protein] lead chloride promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein] lead chloride results in decreased expression of TNF mRNA [lead chloride results in increased abundance of Lead] promotes the reaction [decabromobiphenyl ether results in increased expression of TNF protein]; [lead chloride results in increased abundance of Lead] which results in increased expression of TNF protein; decabromobiphenyl ether promotes the reaction [[lead chloride results in increased abundance of Lead] which results in increased expression of TNF protein]; lead chloride inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:8975779 PMID:15843504 PMID:23503628 PMID:30836164 PMID:36416909 PMID:36646412 More...
|
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TSHB |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
[Hydrocarbons, Chlorinated co-treated with Cadmium Chloride co-treated with lead chloride] results in increased expression of TSHB protein |
CTD |
PMID:12011480 |
|
NCBI chr 1:115,029,826...115,034,309
Ensembl chr 1:115,029,826...115,034,302
|
|
G |
TSPAN7 |
tetraspanin 7 |
increases expression multiple interactions |
EXP |
lead chloride results in increased expression of TSPAN7 mRNA [cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of TSPAN7 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr X:38,561,542...38,688,918
Ensembl chr X:38,561,542...38,688,920
|
|
G |
TUBB |
tubulin beta class I |
increases expression |
EXP |
lead chloride results in increased expression of TUBB protein |
CTD |
PMID:24419708 |
|
NCBI chr 6:30,720,352...30,725,422
Ensembl chr 6:30,717,435...30,725,538
|
|
G |
TUBB4B |
tubulin beta 4B class IVb |
increases expression |
EXP |
lead chloride results in increased expression of TUBB4B protein |
CTD |
PMID:24419708 |
|
NCBI chr 9:137,241,287...137,243,707
Ensembl chr 9:137,241,287...137,243,707
|
|
G |
TYMS |
thymidylate synthetase |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of TYMS mRNA |
CTD |
PMID:18654764 |
|
NCBI chr18:657,653...673,578
Ensembl chr18:657,653...673,578
|
|
G |
UBA1 |
ubiquitin like modifier activating enzyme 1 |
multiple interactions |
ISO |
[[lead chloride results in increased abundance of Lead] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of UBA1 protein; [[lead chloride results in increased abundance of Lead] which co-treated with methylmercuric chloride] results in increased expression of UBA1 protein |
CTD |
PMID:32179164 |
|
NCBI chr X:47,190,847...47,215,128
Ensembl chr X:47,190,861...47,215,128
|
|
G |
UCHL3 |
ubiquitin C-terminal hydrolase L3 |
multiple interactions |
ISO |
[[lead chloride results in increased abundance of Lead] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of UCHL3 protein; [[lead chloride results in increased abundance of Lead] which co-treated with methylmercuric chloride] results in increased expression of UCHL3 protein |
CTD |
PMID:32179164 |
|
NCBI chr13:75,549,502...75,606,020
Ensembl chr13:75,549,483...75,606,020
|
|
G |
UGDH |
UDP-glucose 6-dehydrogenase |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of UGDH mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 4:39,498,755...39,527,439
Ensembl chr 4:39,498,755...39,528,311
|
|
G |
VCP |
valosin containing protein |
decreases expression |
EXP |
lead chloride results in decreased expression of VCP protein |
CTD |
PMID:24419708 |
|
NCBI chr 9:35,056,064...35,072,625
Ensembl chr 9:35,053,928...35,072,668
|
|
G |
VIM |
vimentin |
decreases expression |
EXP |
lead chloride results in decreased expression of VIM protein |
CTD |
PMID:24419708 |
|
NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593
|
|
G |
WNT4 |
Wnt family member 4 |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in decreased expression of WNT4 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr 1:22,117,313...22,143,097
Ensembl chr 1:22,117,313...22,143,969
|
|
G |
YY1 |
YY1 transcription factor |
multiple interactions |
EXP |
[cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] affects the expression of YY1 mRNA |
CTD |
PMID:18654764 |
|
NCBI chr14:100,239,144...100,282,788
Ensembl chr14:100,238,298...100,282,788
|
|